Teleflex(TFX) - 2024 Q3 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Teleflex reported revenues of $764.4 million for Q3 2024, representing a 2.4% year-over-year increase on a GAAP basis and a 2.2% increase on an adjusted constant currency basis, slightly below the guidance of$ 765 million to $770 million due to unexpected softness in the OEM business [6][7] - Adjusted earnings per share for Q3 was$ 3.49, a decrease of 4.1% year-over-year, but higher than expectations due to strong margin performance [7][29] - Adjusted gross margin was 60.8%, a 140 basis point increase year-over-year, primarily driven by the termination of the MSA and the acquisition of Palette, despite manufacturing inefficiencies and cost inflation [26] - Adjusted operating margin was 27.3%, reflecting a 10 basis point year-over-year increase [27] Business Line Data and Key Metrics Changes - Vascular Access revenue increased 6.3% year-over-year to $180.9 million, driven by strong performance in peripheral and central access products [11] - Interventional revenue rose 11.4% year-over-year to$ 149.9 million, with expectations for increased contributions from intra-aortic balloon pump revenues in Q4 [12] - Anesthesia revenue grew 3.4% year-over-year to $101.1 million, led by intraosseous and hemostatic products [12] - Surgical revenue decreased 1% year-over-year to$ 111.7 million, with solid underlying trends offset by tough comparisons in the ligation portfolio [13] - Interventional Urology revenue increased 13.3% year-over-year to $83.4 million, driven by Barrigel revenue following the acquisition of Palette Life Sciences [14] - OEM revenue increased 0.1% year-over-year to$ 82.6 million, softer than expected due to a large customer’s decision to vertically integrate a component [14] Market Data and Key Metrics Changes - Americas revenues were $433.3 million, a 1.5% increase year-over-year, impacted by prior year MSA revenues [8] - EMEA revenues increased 3.9% year-over-year to$ 150.2 million, driven by improved product availability and utilization [8] - Asia revenues were $98.3 million, a 5% increase year-over-year, affected by ongoing doctor strikes in South Korea [9] Company Strategy and Development Direction - The company is focused on driving durable growth through its diversified portfolio and global footprint, with an emphasis on execution and margin expansion [41] - Teleflex is actively pursuing inorganic growth opportunities, including M&A, while maintaining a disciplined capital allocation strategy [41][52] - The integration of Palette Life Sciences is nearly complete, with expectations for continued strong performance from Barrigel and UroLift [80] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment with OEM performance but noted strong margin expansion and free cash flow, positioning the company well for capital allocation [47] - The company anticipates continued headwinds in UroLift and OEM, with expectations for stabilization in 2025 [57] - Management remains optimistic about the intra-aortic balloon pump market, expecting significant share gains in the U.S. due to competitor challenges [19][21] Other Important Information - Cash flow from operations for the year-to-date was$ 435.6 million, up from $372.4 million in the prior year [30] - The company has a cash balance of$ 277.8 million at the end of Q3, with net leverage at approximately 1.7x [31] - Teleflex raised its 2024 revenue guidance for Palette to $73 million to$ 75 million, reflecting strong performance [18] Q&A Session Summary Question: What is the impact of OEM on the top line? - Management clarified that the OEM business was the larger impact on guidance, primarily due to vertical integration and inventory management issues, totaling approximately $14 million for the year [48] Question: How does the company view the balance between share repurchase and M&A? - Management indicated that the balance sheet is strong, allowing for both share repurchase and M&A opportunities, with a focus on non-EPS dilutive assets [50][52] Question: What is the outlook for UroLift and OEM in 2025? - Management noted that the OEM headwind will continue into the first half of next year, while UroLift remains challenged primarily in the office side of service [55][57] Question: What is the expected contribution from intra-aortic balloon pumps in Q4? - Management expects over$ 10 million in orders for intra-aortic balloon pumps in Q4, driven by both normal replacement cycles and conversions from competitors [68][94] Question: How is the integration of Palette Life Sciences progressing? - The integration is nearly complete, with strong performance from Barrigel and expectations for continued growth [80]